MX367192B - Sistemas de cuantificacion de patogenesis y metodos de tratamiento para el enverdecimiento de los citricos. - Google Patents

Sistemas de cuantificacion de patogenesis y metodos de tratamiento para el enverdecimiento de los citricos.

Info

Publication number
MX367192B
MX367192B MX2016005613A MX2016005613A MX367192B MX 367192 B MX367192 B MX 367192B MX 2016005613 A MX2016005613 A MX 2016005613A MX 2016005613 A MX2016005613 A MX 2016005613A MX 367192 B MX367192 B MX 367192B
Authority
MX
Mexico
Prior art keywords
citrus greening
pathogenesis
blight
treatment methods
pathogen
Prior art date
Application number
MX2016005613A
Other languages
English (en)
Other versions
MX2016005613A (es
Inventor
M Lloyd Robert Jr
Original Assignee
Green Life Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Life Biotech Llc filed Critical Green Life Biotech Llc
Publication of MX2016005613A publication Critical patent/MX2016005613A/es
Publication of MX367192B publication Critical patent/MX367192B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un modelo de patogénesis novedoso, método o kit para detectar la patogénesis en un sujeto. En particular, la invención proporciona un índice patógeno obtenido de una relación de la cantidad de dianas de patógeno dual con respecto a la cantidad de medidas cuantitativas de hospedador. El índice patógeno se usa en el diagnóstico, el pronóstico y/o la estrategia de tratamiento de cualquier enfermedad, que incluye las enfermedades de enverdecimiento de los cítricos (HLB). También se proporcionan herramientas de investigación y métodos para el análisis de fármacos para el tratamiento o la prevención de enfermedades de enverdecimiento de los cítricos, así como métodos de tratamiento o prevención de enfermedades de enverdecimiento de los cítricos.
MX2016005613A 2013-10-30 2014-10-30 Sistemas de cuantificacion de patogenesis y metodos de tratamiento para el enverdecimiento de los citricos. MX367192B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361897626P 2013-10-30 2013-10-30
PCT/US2014/063181 WO2015066341A2 (en) 2013-10-30 2014-10-30 Pathogenesis quantification systems and treatment methods for citrus greening blight

Publications (2)

Publication Number Publication Date
MX2016005613A MX2016005613A (es) 2016-12-20
MX367192B true MX367192B (es) 2019-08-08

Family

ID=53005380

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005613A MX367192B (es) 2013-10-30 2014-10-30 Sistemas de cuantificacion de patogenesis y metodos de tratamiento para el enverdecimiento de los citricos.

Country Status (6)

Country Link
US (2) US10351918B2 (es)
EP (1) EP3063272A2 (es)
JP (1) JP2016538882A (es)
CN (1) CN105722977A (es)
MX (1) MX367192B (es)
WO (1) WO2015066341A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX367192B (es) 2013-10-30 2019-08-08 Green Life Biotech Llc Sistemas de cuantificacion de patogenesis y metodos de tratamiento para el enverdecimiento de los citricos.
US10612075B2 (en) * 2015-12-28 2020-04-07 PathogenDX Inc Microarray based multiplex pathogen analysis and uses thereof
US10501814B2 (en) * 2015-12-28 2019-12-10 PathogenDX Inc Microarray based multiplex pathogen analysis and uses thereof
US10513745B2 (en) * 2015-12-28 2019-12-24 PathogenDX Inc Microarray based multiplex pathogen analysis and uses thereof
BR112018069596A2 (pt) * 2016-03-25 2019-01-29 Univ California detecção de huanglongbing (hlb) em plantas cítricas analisando alterações em compostos orgânicos voláteis emitidos
DE102016207147A1 (de) * 2016-04-27 2017-11-02 Nordkorn Saaten Gmbh Verfahren zum Nachweis von biologisch aktiven Pflanzenpathogenen
CN106929584A (zh) * 2017-03-30 2017-07-07 上海市农业科学院 一种检测Camv35S启动子的RPA引物、试剂盒及检测方法
WO2020102537A1 (en) * 2018-11-14 2020-05-22 Washington State University Host-free 'candidatus liberibacter asiaticus' culture
US11170872B2 (en) 2019-11-05 2021-11-09 Apeel Technology, Inc. Prediction of latent infection in plant products
WO2021257007A1 (en) * 2020-06-15 2021-12-23 Mahidol University An antiviral pharmaceutical composition with therapeutic agent originated from astraeus asiaticus
CN111944919B (zh) * 2020-07-31 2023-05-26 广东省农业科学院果树研究所 一种可以在田间、常温操作的香蕉枯萎病菌热带4号小种可视化检测技术体系
CN112280879A (zh) * 2020-11-17 2021-01-29 广东省农业科学院植物保护研究所 一种快速检测柑橘黄龙病亚洲种的rpa引物、试剂盒及其检测方法与应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3529478A1 (de) 1985-08-16 1987-02-19 Boehringer Mannheim Gmbh 7-desaza-2'desoxyguanosin-nukleotide, verfahren zu deren herstellung und deren verwendung zur nukleinsaeure-sequenzierung
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
CA2039517C (en) 1990-04-03 2006-11-07 David Segev Dna probe signal amplification
US6787338B2 (en) 1990-06-04 2004-09-07 The University Of Utah Method for rapid thermal cycling of biological samples
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
JP3739785B2 (ja) 1991-11-26 2006-01-25 アイシス ファーマシューティカルズ，インコーポレイティド 修飾されたピリミジンを含有するオリゴマーを使用する増強された三重らせんおよび二重らせんの成形
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
WO1995007086A1 (en) 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US5972716A (en) 1994-04-29 1999-10-26 The Perkin-Elmer Corporation Fluorescence monitoring device with textured optical tube and method for reducing background fluorescence
US5545527A (en) 1994-07-08 1996-08-13 Visible Genetics Inc. Method for testing for mutations in DNA from a patient sample
US5834189A (en) 1994-07-08 1998-11-10 Visible Genetics Inc. Method for evaluation of polymorphic genetic sequences, and the use thereof in identification of HLA types
US6800452B1 (en) 1994-08-08 2004-10-05 Science Applications International Corporation Automated methods for simultaneously performing a plurality of signal-based assays
JPH11512397A (ja) 1995-09-07 1999-10-26 ユニバーシティー オブ ジョージア リサーチ ファウンデーション，インコーポレイテッド 治療用アジド化合物
US5795722A (en) 1997-03-18 1998-08-18 Visible Genetics Inc. Method and kit for quantitation and nucleic acid sequencing of nucleic acid analytes in a sample
US6265152B1 (en) 1995-12-22 2001-07-24 Visible Genetics Inc. Method and kit for evaluation of HIV mutations
US6007983A (en) 1995-12-22 1999-12-28 Visible Genetics Inc. Method and kit for evaluation of HIV mutations
US6180777B1 (en) 1996-01-12 2001-01-30 Bayer Corporation Synthesis of branched nucleic acids
FR2746413B1 (fr) 1996-03-19 1998-04-24 Bio Merieux Detection d'une sequence nucleotidique avec amplification de signal
US6830887B2 (en) 1997-03-18 2004-12-14 Bayer Healthcare Llc Method and kit for quantitation and nucleic acid sequencing of nucleic acid analytes in a sample
ATE280177T1 (de) 1997-03-20 2004-11-15 Hoffmann La Roche Modifizierte primer
WO1999011813A2 (en) 1997-09-04 1999-03-11 Bayer Corporation Oligonucleotide probes bearing quenchable fluorescent labels, and methods of use thereof
MXPA00008348A (es) 1998-02-25 2005-07-15 Univ Emory 2-fluronucleosidos.
ES2369818T3 (es) 1998-11-09 2011-12-07 Eiken Kagaku Kabushiki Kaisha Procedimiento de síntesis de ácido nucleico.
US7635690B2 (en) 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7115584B2 (en) 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
WO2000056920A1 (en) 1999-03-18 2000-09-28 Exiqon A/S One step sample preparation and detection of nucleic acids in complex biological samples
DE60029314T2 (de) 1999-03-24 2007-07-12 Exiqon A/S Verbesserte Synthese für -2.2.1. I Bicyclo-Nukleoside
US6734291B2 (en) 1999-03-24 2004-05-11 Exiqon A/S Synthesis of [2.2.1]bicyclo nucleosides
DE60119533T2 (de) 2000-05-01 2007-05-16 Eiken Kagaku K.K. Verfahren zur erkennung des produkts einer nukleinsäuresynthetisierungsreaktion
ATE437225T1 (de) 2000-09-19 2009-08-15 Eiken Chemical Verfahren zur polynukleotidsynthese
ES2310237T3 (es) 2002-02-21 2009-01-01 Asm Scientific, Inc. Amplificacion por recombinasa polimerasa.
US7399590B2 (en) 2002-02-21 2008-07-15 Asm Scientific, Inc. Recombinase polymerase amplification
US7662594B2 (en) 2002-09-20 2010-02-16 New England Biolabs, Inc. Helicase-dependent amplification of RNA
US7282328B2 (en) 2002-09-20 2007-10-16 New England Biolabs, Inc. Helicase dependent amplification of nucleic acids
CA2503446C (en) * 2002-10-24 2012-12-18 Paratek Pharmaceuticals, Inc. Methods of using substituted tetracycline compounds to modulate rna
US7759061B2 (en) 2004-06-02 2010-07-20 Twistdx, Inc. 2′-nitrobenzyl-modified ribonucleotides
US7629124B2 (en) 2006-06-30 2009-12-08 Canon U.S. Life Sciences, Inc. Real-time PCR in micro-channels
EP3042660A3 (en) 2008-04-15 2016-10-26 RFS Pharma, LLC. Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
US9758837B2 (en) * 2011-08-02 2017-09-12 The United States Of America, As Represented By The Secretary Of Agriculture Sensitive and rapid method for Candidatus Liberibacter species detection
MX367192B (es) 2013-10-30 2019-08-08 Green Life Biotech Llc Sistemas de cuantificacion de patogenesis y metodos de tratamiento para el enverdecimiento de los citricos.

Also Published As

Publication number Publication date
US10351918B2 (en) 2019-07-16
WO2015066341A2 (en) 2015-05-07
US20160319379A1 (en) 2016-11-03
EP3063272A2 (en) 2016-09-07
MX2016005613A (es) 2016-12-20
WO2015066341A3 (en) 2015-11-12
US20190300971A1 (en) 2019-10-03
US10815537B2 (en) 2020-10-27
CN105722977A (zh) 2016-06-29
JP2016538882A (ja) 2016-12-15

Similar Documents

Publication Publication Date Title
MX2016005613A (es) Sistemas de cuantificacion de patogenesis y metodos de tratamiento para el enverdecimiento de los citricos.
HK1199099A1 (en) Methods and compositions for the treatment and diagnosis of cancer
GB2528205A (en) Systems and methods to detect rare mutations and copy number variation
WO2014151006A3 (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
MX367963B (es) Métodos para detectar mutaciones raras y variación en el número de copias.
WO2012135844A3 (en) Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers
MX368959B (es) Inhibidores heteroarilo de pde4.
WO2013008102A3 (en) Methods and compositions for evaluating and/or treating chronic immune diseases
EP4553840A3 (en) Systems and methods for analyzing nucleic acid
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
EA201491339A1 (ru) Замещенные аннеллированные пиримидины и триазины и их применение
EA201490546A1 (ru) Замещенные аннелированные пиримидины и их применение
EP4321866A3 (en) Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
WO2013182912A3 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
IN2014KN02933A (es)
MX2018001831A (es) Biomarcadores para el tratamiento de alopecia areata.
WO2014028862A9 (en) Use of dna in circulating exosomes as a diagnostic marker for metastasic disease
WO2012012278A3 (en) Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
EP2703488A4 (en) COMPOSITION TO PREDICT SENSITIVITY TO TRASTUZUMAB THERAPY IN BREAST CANCER PATIENTS AND METHODS THEREFOR
CA2888908A1 (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
EA201591773A1 (ru) Макроциклические ингибиторы rip2-киназы
EP3444362A3 (en) Circulating mirnas as early detection marker and prognostic marker
HK1251171A1 (zh) 肿瘤生物标志物及其应用

Legal Events

Date Code Title Description
FG Grant or registration